Keywords: Biogen Idec, 2009 financial results, Tysabri, Rituxan, Avonex
Biogen Idec 2009 results beat forecasts, boosted by Tysabri sales growth
Article | 10 February 2010
US biotechnology firm Biogen Idec reported total revenues for full-year 2009 of $4.4 billion, an increase of 7% on 2008. On a reported basis, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
